Proteome Sciences plc

LSE:PRM.L

Sector

🏥 Health Care

Industries

📊 Big Data

🧬 Biotechnology

🔬 Clinical Trials

📈 Financial Reports

💊 Pharmaceuticals

Location

United Kingdom

Market Cap

USD 13.47 M

Share Price

USD 0.04

Avg Daily Volume

229,016

Change (1 day)

1.54%

Change (1 year)

-17.40%

Change (YTD)

-3.90%

Proteome Sciences plc Current Assets for the year ending December 31, 2024: USD 3.24 M

Proteome Sciences plc Current Assets is USD 3.24 M for the year ending December 31, 2024, a -38.84% change year over year. Current assets are assets that are expected to be converted into cash or used within one year.

Proteome Sciences plc Current Assets for the year ending December 31, 2023 was USD 5.30 M, a -100.00% change year over year.
Proteome Sciences plc Current Assets for the year ending December 31, 2022 was USD 305.64 B, a -6.01% change year over year.
Proteome Sciences plc Current Assets for the year ending December 31, 2021 was USD 325.20 B, a 22.95% change year over year.
Proteome Sciences plc Current Assets for the year ending December 31, 2020 was USD 264.51 B, a 30.14% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Current Assets	Property, Plant, Equipment (Net)	Total Assets	Accounts Payable

LSE: PRM.L

Proteome Sciences plc

CEO	Mr. Christopher Donovan James Pearce Dip., MSI
IPO Date	Oct. 3, 1995
Location	United Kingdom
Headquarters	Coveham House
Employees	36
Sector	🏥 Health Care
Industries Big Data 🧬 Biotechnology 🔬 Clinical Trials 📈 Financial Reports 💊 Pharmaceuticals

Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.